Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Mar;51(3):1085-8.
doi: 10.1128/AAC.00954-06. Epub 2006 Dec 11.

Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis

Juyan Zhou  1 , Yunhua Chen, Setareh Tabibi, Luis Alba, Elizabeth Garber, Lisa Saiman
Affiliations

Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis

Juyan Zhou et al. Antimicrob Agents Chemother. 2007 Mar.

Abstract

Susceptibility (18 antimicrobial agents including high-dose tobramycin) and checkerboard synergy (23 combinations) studies were performed for 2,621 strains of Burkholderia cepacia complex isolated from 1,257 cystic fibrosis patients. Minocycline, meropenem, and ceftazidime were the most active, inhibiting 38%, 26%, and 23% of strains, respectively. Synergy was rarely noted (range, 1% to 15% of strains per antibiotic combination).

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
The distributions of MICs for Burkholderia cepacia complex bacteria isolated from patients with CF in 1996 (n = 187), 1998 (n = 239), 2001 (n = 382), and 2004 (n = 302) are shown for the selected agents ceftazidime, meropenem, minocycline, and trimethoprim-sulfamethoxazole. The highest concentrations of antibiotics tested varied during the study period for some agents. For ceftazidime, the highest concentration tested in 1996 was 128 μg/ml and in 2001 and 2004 the highest concentration tested was 64 μg/ml. Strains not inhibited by 128 μg/ml are depicted as an MIC of >128 μg/ml. For meropenem, the highest concentration tested in 1998 was 16 μg/ml and in 2001 and 2004 the highest concentration tested was 64 μg/ml. Strains that were not inhibited by 64 μg/ml are depicted as an MIC of >64 μg/ml.
See this image and copyright information in PMC

References

    1. Aaron, S. D., W. Ferris, D. A. Henry, D. P. Speert, and N. E. MacDonald. 2000. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am. J. Respir. Crit. Care Med. 161:1206-1212. - PubMed
    1. Aaron, S. D., K. L. Vandemheen, W. Ferris, D. Fergusson, E. Tullis, D. Haase, Y. Berthiaume, N. Brown, P. Wilcox, V. Yozghatlian, P. Bye, S. Bell, F. Chan, B. Rose, A. Jeanneret, A. Stephenson, M. Noseworthy, A. Freitag, N. Paterson, S. Doucette, C. Harbour, M. Ruel, and N. MacDonald. 2005. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366:463-471. - PubMed
    1. Bevivino, A., C. Dalmastri, S. Tabacchioni, L. Chiarini, M. L. Belli, S. Piana, A. Materazzo, P. Vandamme, and G. Manno. 2002. Burkholderia cepacia complex bacteria from clinical and environmental sources in Italy: genomovar status and distribution of traits related to virulence and transmissibility. J. Clin. Microbiol. 40:846-851. - PMC - PubMed
    1. Blumer, J. L., L. Saiman, M. W. Konstan, and D. Melnick. 2005. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 128:2336-2346. - PubMed
    1. Burns, J. L., and L. Saiman. 1999. Burkholderia cepacia infections in cystic fibrosis. Pediatr. Infect. Dis. J. 18:155-156. - PubMed

Publication types

MeSH terms

Substances